CompletedNCT04952597Updated Oct 26, 2024Results posted

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

A Phase 2 interventional study of Ociperlimab and Tislelizumab in Limited Stage Small Cell Lung Cancer, sponsored by BeiGene. Completed at 33 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Phase: Phase 2
Study type: Interventional
Enrollment: 126
Allocation: Randomized
Ages: 18 Years and older
Sex: All

Study summary

This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of Limited-Stage Small Cell Lung Cancer (LS-SCLC) participants .

Conditions studied

Limited Stage Small Cell Lung Cancer

Browse trials for

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's enrollment of 126 is above the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

BeiGene is the lead sponsor of 122 studies on the registry; 3 are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 31 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Eligibility criteria

Key Inclusion Criteria:

Participant has pathologically (histologically or cytologically) proven diagnosis of small cell lung cancer
Has limited-stage disease (stage Tx, T1-T4, N0-3, M0; AJCC staging, 8th edition), and can be safely treated with definitive radiation doses.
Participant has not received any prior treatment for LS-SCLC.
Participant has measurable disease as assessed according to RECIST v1.1 that is appropriate for selection as a target lesion for repeat measurement, as determined by local site investigator/radiology review
ECOG Performance Status ≤ 2 assessed within 7 days before the first administration of study intervention, and must have a life expectancy of ≥ 12 weeks.

Key Exclusion Criteria:

Mixed small cell lung cancer histology. Note: mixed SCLC with the component of neuroendocrine carcinoma origin is considered eligible
Have received surgical resection for LS-SCLC
Any participant for whom the tumor is considered resectable by surgery or stereotactic body radiation therapy/stereotactic ablative radiotherapy should be considered ineligible
Is expected to require any other form of antineoplastic therapy while on study.
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-TIGIT, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways

Note: Other protocol-defined Inclusion/Exclusion criteria may apply

Study design

Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: None (open label)
Enrollment: 126 participants (actual)

Study arms

Experimental
Arm A: Ociperlimab + Tislelizumab
Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab
Drug: Ociperlimab · Drug: Tislelizumab · Drug: Concurrent Chemoradiotherapy
Experimental
Arm B: Tislelizumab
Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone
Drug: Tislelizumab · Drug: Concurrent Chemoradiotherapy
Experimental
Arm C: Concurrent Chemoradiotherapy (cCRT)
cCRT only for 4 cycles at the investigator's discretion
Drug: Concurrent Chemoradiotherapy

Interventions

DrugOciperlimab
Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle
Also known as: BGB-A1217
DrugTislelizumab
Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle
Also known as: BGB-A317
DrugConcurrent Chemoradiotherapy
Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles. Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)

What researchers measure

Primary outcomes

Progression Free Survival (PFS)
Defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)
Time frame: Up to approximately 2 years

Secondary outcomes

Complete Response Rate (CR)
defined as the percentage of participants who had CR as assessed by the investigator per RECIST v1.1
Time frame: Up to approximately 2 years
Overall Response Rate (ORR)
defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1
Time frame: Up to approximately 2 years
Overall Response Rate (ORR) in the Programmed Death-Ligand 1 (PD-L1) Analysis Set
defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1
Time frame: Up to approximately 2 years
Overall Response Rate (ORR) in the T Cell Immunoreceptor With Immunoglobulin and ITIM Domain (TIGIT) Analysis Set
defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1
Time frame: Up to approximately 2 years
Duration of Response (DOR)
defined as the time from the date of the first occurrence of a documented objective response to the date of documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)
Time frame: Up to approximately 2 years
Overall Survival (OS) in the ITT Analysis Set
Defined as the time from the date of randomization to the date of death due to any cause
Time frame: Up to approximately 2 years
Overall Survival (OS) in the PD-L1 Analysis Set
defined as the time from the date of randomization to the date of death due to any cause
Time frame: Up to approximately 2 years
Overall Survival (OS) in the TIGIT Analysis Set
defined as the time from the date of randomization to the date of death due to any cause
Time frame: Up to approximately 2 years
Distant Metastasis-free Survival (DMFS)
defined as the time from the date of randomization to the date of the first documented distant metastasis as assessed by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)
Time frame: Up to approximately 2 years
PFS in the PD-L1 Analysis Set
defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first),
Time frame: Up to approximately 2 years
PFS in the TIGIT Analysis Set
defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first),
Time frame: Up to approximately 2 years
Number of Participants Experiencing Adverse Events (AEs)
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.03
Time frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years

Results

Posted Sep 19, 2024

Participant flow

Participants were enrolled in multiple study centers in China, South Korea, and the United States.

Participant flow — Overall Study
Milestone	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
Started	41	42	43
Completed	28	28	25
Not completed	13	14	18
Withdrew: Death	12	13	14
Withdrew: Withdrawal by subject	1	0	3
Withdrew: Lost to follow-up	0	1	1

Outcome measures

PrimaryProgression Free Survival (PFS)

Defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)

Time frame:: Up to approximately 2 years
Reported as:: Median · Months

Progression Free Survival (PFS)
Months	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
Progression Free Survival (PFS)	12.6 (8.7 to NA)	13.2 (8.5 to NA)	9.5 (8.3 to 14.4)

SecondaryComplete Response Rate (CR)

defined as the percentage of participants who had CR as assessed by the investigator per RECIST v1.1

Time frame:: Up to approximately 2 years
Reported as:: Number · percentage of participants

Complete Response Rate (CR)
percentage of participants	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
Complete Response Rate (CR)	7.3 (1.5 to 19.9)	9.5 (2.7 to 22.6)	2.3 (0.1 to 12.3)

SecondaryOverall Response Rate (ORR)

defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1

Time frame:: Up to approximately 2 years
Reported as:: Number · percentage of participants

Overall Response Rate (ORR)
percentage of participants	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
Overall Response Rate (ORR)	85.4 (70.8 to 94.4)	88.1 (74.4 to 96.0)	76.7 (61.4 to 88.2)

SecondaryOverall Response Rate (ORR) in the Programmed Death-Ligand 1 (PD-L1) Analysis Set

defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1

Time frame:: Up to approximately 2 years
Reported as:: Number · percentage of participants

Overall Response Rate (ORR) in the Programmed Death-Ligand 1 (PD-L1) Analysis Set
percentage of participants	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
PD-L1 Expression in TAP ( >=1%)	85.7 (57.2 to 98.2)	94.1 (71.3 to 99.9)	76.5 (50.1 to 93.2)
PD-L1 Expression in TAP (<1%)	93.8 (69.8 to 99.8)	81.8 (48.2 to 97.7)	86.7 (59.5 to 98.3)

SecondaryOverall Response Rate (ORR) in the T Cell Immunoreceptor With Immunoglobulin and ITIM Domain (TIGIT) Analysis Set

defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1

Time frame:: Up to approximately 2 years
Reported as:: Number · percentage of participants

Overall Response Rate (ORR) in the T Cell Immunoreceptor With Immunoglobulin and ITIM Domain (TIGIT) Analysis Set
percentage of participants	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
TIGIT Expression Level in IC (>=1%)	88.9 (65.3 to 98.6)	88.0 (68.8 to 97.5)	93.8 (69.8 to 99.8)
TIGIT Expression Level in IC (<1%)	86.7 (59.5 to 98.3)	100.0 (59.0 to 100.0)	68.4 (43.4 to 84.4)

SecondaryDuration of Response (DOR)

defined as the time from the date of the first occurrence of a documented objective response to the date of documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)

Time frame:: Up to approximately 2 years
Reported as:: Median · Months

Duration of Response (DOR)
Months	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
Duration of Response (DOR)	10.1 (6.0 to NA)	11.5 (6.9 to NA)	8.2 (5.6 to NA)

SecondaryOverall Survival (OS) in the ITT Analysis Set

Defined as the time from the date of randomization to the date of death due to any cause

Time frame:: Up to approximately 2 years
Reported as:: Median · months

Overall Survival (OS) in the ITT Analysis Set
months	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
Overall Survival (OS) in the ITT Analysis Set	NA (NA to NA)	NA (19.8 to NA)	NA (20.0 to NA)

SecondaryOverall Survival (OS) in the PD-L1 Analysis Set

defined as the time from the date of randomization to the date of death due to any cause

Time frame:: Up to approximately 2 years
Reported as:: Median · months

Overall Survival (OS) in the PD-L1 Analysis Set
months	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
PD-L1 Expression in TAP (>=1%)	NA (12.2 to NA)	NA (17.6 to NA)	NA (16.5 to NA)
PD-L1 Expression in TAP (<1%)	NA (13.1 to NA)	NA (7.3 to NA)	NA (13.3 to NA)

SecondaryOverall Survival (OS) in the TIGIT Analysis Set

defined as the time from the date of randomization to the date of death due to any cause

Time frame:: Up to approximately 2 years
Reported as:: Median · months

Overall Survival (OS) in the TIGIT Analysis Set
months	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
TIGIT Expression Level in IC (>=1%)	NA (NA to NA)	NA (NA to NA)	NA (20.0 to NA)
TIGIT Expression Level in IC (<1%)	NA (12.0 to NA)	NA (17.6 to NA)	NA (13.3 to NA)

SecondaryDistant Metastasis-free Survival (DMFS)

defined as the time from the date of randomization to the date of the first documented distant metastasis as assessed by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)

Time frame:: Up to approximately 2 years
Reported as:: Median · months

Distant Metastasis-free Survival (DMFS)
months	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
Distant Metastasis-free Survival (DMFS)	17.9 (9.7 to NA)	15.3 (9.8 to NA)	20.0 (8.6 to NA)

SecondaryPFS in the PD-L1 Analysis Set

defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first),

Time frame:: Up to approximately 2 years
Reported as:: Median · months

PFS in the PD-L1 Analysis Set
months	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
PD-L1 Expression in TAP ( >=1%)	12.6 (7.8 to NA)	15.0 (8.5 to NA)	11.1 (8.1 to NA)
PD-L1 Expression in TAP (<1%)	10.3 (5.7 to NA)	14.8 (4.0 to NA)	14.4 (7.9 to NA)

SecondaryPFS in the TIGIT Analysis Set

Time frame:: Up to approximately 2 years
Reported as:: Median · months

PFS in the TIGIT Analysis Set
months	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
TIGIT Expression Level in IC (>=1%)	17.9 (9.5 to NA)	14.3 (7.1 to NA)	11.2 (8.3 to NA)
TIGIT Expression Level in IC (<1%)	8.7 (5.5 to 12.6)	NA (8.3 to NA)	14.4 (7.2 to NA)

SecondaryNumber of Participants Experiencing Adverse Events (AEs)

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.03

Time frame:: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Reported as:: Count of participants · Participants

Number of Participants Experiencing Adverse Events (AEs)
Participants	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
Number of Participants with at least one TEAE	41	42	43
Number of participants with at least one SAE	25	20	12

Adverse events

Collected over All-cause mortality and adverse events (AEs): From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
Group	Deaths	Serious	Other
Arm A: Ociperlimab + Tislelizumab	12/41 (29.3%)	25/41 (61%)	41/41 (100%)
Arm B: Tislelizumab	13/42 (31%)	20/42 (47.6%)	42/42 (100%)
Arm C: Concurrent Chemoradiotherapy (cCRT)	14/43 (32.6%)	12/43 (27.9%)	43/43 (100%)

Most frequent serious events

Showing 10 of 38

Most frequent serious events
Event	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
PneumoniaInfections and infestations	6/41	3/42	0/43
Platelet count decreasedInvestigations	6/41	3/42	4/43
Neutrophil count decreasedInvestigations	5/41	5/42	3/43
White blood cell count decreasedInvestigations	5/41	2/42	3/43
PneumonitisRespiratory, thoracic and mediastinal disorders	4/41	2/42	1/43
Radiation pneumonitisInjury, poisoning and procedural complications	3/41	3/42	1/43
Radiation oesophagitisInjury, poisoning and procedural complications	0/41	3/42	3/43
AnaemiaBlood and lymphatic system disorders	2/41	0/42	1/43
HyponatraemiaMetabolism and nutrition disorders	2/41	0/42	1/43
Febrile neutropeniaBlood and lymphatic system disorders	0/41	2/42	0/43

Most frequent other events

Showing 10 of 92

Most frequent other events
Event	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)
AnaemiaBlood and lymphatic system disorders	37/41	38/42	38/43
NauseaGastrointestinal disorders	34/41	32/42	28/43
AlopeciaSkin and subcutaneous tissue disorders	29/41	33/42	33/43
White blood cell count decreasedInvestigations	32/41	31/42	26/43
Neutrophil count decreasedInvestigations	28/41	31/42	24/43
VomitingGastrointestinal disorders	22/41	29/42	15/43
Platelet count decreasedInvestigations	26/41	24/42	22/43
Decreased appetiteMetabolism and nutrition disorders	21/41	25/42	18/43
ConstipationGastrointestinal disorders	24/41	19/42	13/43
HyponatraemiaMetabolism and nutrition disorders	16/41	21/42	16/43

Baseline characteristics

The Intent-To-Treat (ITT) Analysis Set includes all randomized patients.

Age, Continuous
Age, Continuous(years)	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)	Total
Mean	60.5 ± 9.50	59.9 ± 7.11	61.0 ± 9.54	60.5 ± 8.73

Sex: Female, Male
Sex: Female, Male(Participants)	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)	Total
Female	10	9	8	27
Male	31	33	35	99

Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)	Arm A: Ociperlimab + Tislelizumab	Arm B: Tislelizumab	Arm C: Concurrent Chemoradiotherapy (cCRT)	Total
Asian	41	42	42	125
White	0	0	1	1

Study locations

33 sites

Tennessee Cancer Specialist
Knoxville, Tennessee 37909, United States
Peking University First Hospital
Beijing, Beijing 100034, China
Beijing Cancer Hospital
Beijing, Beijing 100142, China
Gansu Provincial Cancer Hospital
Lanzhou, Gansu 730050, China
The First Affiliated Hospital, Sun Yat Sen University
Guangzhou, Guangdong 510080, China
The Tumor Hospital Affiliated to Guangxi Medical University
Nanning, Guangxi 530021, China
Henan Cancer Hospital
Zhengzhou, Henan 450000, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan 450052, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei 430022, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan 410011, China
Hunan Cancer Hospital
Changsha, Hunan 410013, China
Huai An First Peoples Hospital
Huaian, Jiangsu 223300, China
Nanjing Chest Hospital
Nanjing, Jiangsu 210029, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu 221000, China
Hanzhong Central Hospital
Hanzhong, Shaanxi 72300, China
Qilu Hospital of Shandong University
Jinan, Shandong 250000, China
Linyi Cancer Hospital
Linyi, Shandong 276001, China
Qingdao Central Hospital
Qingdao, Shandong 266031, China
Yantai Yuhuangding Hospital
Yantai, Shandong 264000, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai 200000, China
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai 200032, China
West China Hospital, Sichuan University
Chengdu, Sichuan 610041, China
Affiliated Hospital of North Sichuan Medical College
Nanchong, Sichuan 637000, China
Tianjin Medical University General Hospital
Tianjin, Tianjin 300052, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin 300060, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan 650000, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang 310022, China
Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)
Ningbo, Zhejiang 315000, China
Chungbuk National University Hospital
Cheongjusi, Chungcheongbukdo 28644, Korea, Republic of
Cha Bundang Medical Center, Cha University
Gyeonggido, Gyeonggi-do 13496, Korea, Republic of
The Catholic University of Korea, St Vincents Hospital
Suwonsi, Gyeonggi-do 16247, Korea, Republic of
Ajou University Hospital
Suwonsi, Gyeonggi-do 16499, Korea, Republic of
Kyungpook National University Chilgok Hospital
Daegu, Gyeongsangbukdo 41404, Korea, Republic of

References and documents

Publications

Youling Gong, Qingsong Pang, Rong Yu, Zhengfei Zhu, Jiangqiong Huang, Yufeng Cheng, Diansheng Zhong, Hongbo Wu, Seung Soo Yoo, Tracy Dobbs, Zinan Bao, Yunxia Zuo, Boxian Wei, Pu Sun, You Lu; Abstract CT255: AdvanTIG-204: A phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC). Cancer Res 1 April 2024; 84 (7_Supplement): CT255. https://doi.org/10.1158/1538-7445.AM2024-CT255

Study documents

Study protocol · Oct 8, 2021
Statistical analysis plan · Aug 22, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT04952597
Lead sponsor: BeiGene
Responsible party: Sponsor
First posted: Jul 7, 2021
Start date: Jul 15, 2021
Primary completion: Jul 26, 2023
Completion: Jul 26, 2023
Results posted: Sep 19, 2024
Last update: Oct 26, 2024

Study contacts

BeiGene

study director · Study Director

Oversight

FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Neoplasms→

Other studies from this sponsor

BeiGene

Start the discussion